Member Info for SocialistB

Because there would NOT be a proudness of having stood the distance, having backed the right thing, having done the right thing, hung on when it was hard. Because there would be a proudness of having stood the distance, having backed the right thing, having done the right thing, hung on when it was hard.

sorry forgot the important word "NOT"

Buying in now for the first, now wouldn't that be something.

The company has again managed to secure funds and have a proven track record that they have a knack for this ability, now that ought to give some confidence to new (and old) shareholders.

They have proven on 2 patients that HG-CT-1:

Is safe and well tolerated

But most importantly that there is efficacy.

In other words, it works.

What we do not know yet is we can obtain the same positive results as in the mice models.

But what a time to make an investment.

What a time to take a gamble.

Some out there are that lucky, they are now given this opportunity.

Would I wish it was me?

From a purely financial point of view, sure.

But otherwise NO.

Because there would be a proudness of having stood the distance, having backed the right thing, having done the right thing, hung on when it was hard.

But for anyone not thinking like that, buying in now is an fantastic opportunity, there is always the proudness of investing near the bottom and see the possibility before most figure it out.

That is also something to be proud of.

And this might be almost as good as it gets.

Unless free money can be obtained, there WILL be further dilution, it is as simple as that.

There are rent and salaries to be paid and an active clinical trial going on at the moment.

All has to be paid.

And we got no income stream.

The money has to come from somewhere.

If not, then it is goodnight for the company.

Bar free money, there will always be dilution when accepting money making a deal.

I quite frankly don't care if it is a further round on the market or if it is a JV or VC.

I care about the company getting money to progress and prove up our candidates.

And the BOD has proven they are capable in a difficult financial market to raise funds.

Discount or giving a percentage away, either way, we are talking dilution.

We are always talking dilution unless there is such a thing as free lunch.

HG-CT-1 has been well tolerated by the 2nd Patient.

I am sure they have been drinking water as well in the past weeks and that has neither had a negative effect.

So why the excitement?

Well water is needed to stay alive and now there are signs that if you are so unlucky that you have got AML you need HG-CT-1 too, to stay alive as it shows efficacy.

So it is rather important that HG-CT-1 is safe.

And so far all evidence available shows that it is.

But best of all is the signs of efficacy.

HG-CT-1 would be worthless without efficacy.

Well tolerated from a safety point of view and efficacy, that sets HG-CT-1 far apart from water, which is also important to stay alive, and that is the point.

All the best wishes to Patients 1,2 and soon number 3, may they all do well and us by extension as well.

The BBC this morning was mention a case where a woman had been given a 30 percent chance of survival.

Besides surgery she was given immunotherapy and she have now exceeded 5 years since then.

Good for her.

Good for the name of immunotherapy

And therefore by extension good for HG-CT-1

We know PT 1 and 2 are now home, after receiving just one shot.

And we assume they are doing well, based both on the news and lack of news we got so far.

News like today, makes me more confident about HG-CT-1

Now it's just a waiting game for the results

@MrsIndia

I get your frustration.

But isn't this how it is when we invest in a company with nothing but expenditure and no product to sell.

With no income whatsoever, we rely on other people being willing to pay a higher price on good news.

And there has mostly been good news coming from Hemogenyx.

But there has been a lack of new investors willing to pay a higher price, there simply has not been enough demand, but in my view Hemogenyx have done what they could to create demand by delivering excellent science.

It's just a shame the excellent science did not result in an excellent share price as well.

I doubt very much that things have gone as the BOD had hoped regarding raising funds.

It certainly has not gone as I had expected.

But I applaud the BOD for continuously managing to raise funds in a difficult climate and keep the ship afloat.

In my view they have done their job.

It ought to be obviously to everyone that there has not yet been a fantastic offer on the table, I think here in regard to both terms and conditions and money.

Had there been, then I am sure the BOD would have accepted, rather then have to raise at what amounts to half a penny in old money.

We should all have done what the former staunch defender of Hemogenyx, Hedgehogarth did a long time ago, sell up and then come back at a later date.

But hey, we can't all be that smart (but I certainly wish I had been)

On the other side, there is also an immense pride in having been here on rocky journey.

Hopefully we can soon sing jolly songs and look back on the troubled times with a kind of joy.

But the share price has to rise first, that's a prerequisite

@HereForHemo

Although you might be right that the clinical trial is Mr Sandler's priority, then I am sure that the AGM is weighing heavily on his mind or at least it should when he and the BOD are asking for permission to double the number of shares in issue, if I understand the 100 percent of issuing new shares correct.

For arguments sake, someone who owns 4 percent would suddenly only own 2 percent.

Annoying as that might be, I doubt many will moan to much if the cake gets 10-20 times bigger.

But it would be nice with a reassurance that that will be the case.

And if not much can be said for legal or business reasons, then I agree that a relaxed attitude from Mr Sandler and the BOD could be a sign of good things to come.

As we have the AGM tomorrow, I hoped we'd receive an 0700 RNS this morning regarding the efficacy of HG-CT-1.

That has not happened.

But there is still the rest of today and the beginning of tomorrow.

I know these results cannot be published before they are ready and verified.

It's just that, it would be so nice to hear the positive outcome that I am hoping for before the AGM.

Here's to hoping

@ConsDoms.

From the RNS from the 8/5/2025:

"These warrants will be exercisable for a period of 36 months at an exercise price of 270 pence "

I assume this was the price you were asking about!

That means the buyer of the most recent issued shares, either have sold enough shares to come below the 3 percent threshold or they are not giving a toss about the rules and regulations and are breaking the law.

Let's assume they are a law abiding citizen.

They might have sold the whole lot at a small loss or just enough to bring them below the 3 percent.

As I recall it, the buyer was an existing shareholder, so let's assume they might have had to part ways with half of the newly acquired shares, but it could easily be more depending on how big a player they were beforehand.

If we use the following numbers for illustration

180 Buy

175 Sell

The loss is 5 pence

5 / 180 X 100 equals 2.77 percent

If the buyer has sold for 225000 pounds (roughly 50 percent)

Then it amounts to a loss of 8122

If the buyer has sold the whole lot, the loss can be doubled up.

Personally I'd go for the 50 percent option.

A loss of 8000 pounds, seems like a good deal not to have to issue a TR1 both now and when selling.

And still have the option to buy 250000 shares at what we all hope will be a VERY favourable price in not to distant a future.

Meanwhile the science it ticking along and it all looks very promising from where I am sitting.

A placee has handed over 400.000 to Hemogenyx, that is a lifeline to the company and thereby us by extension.

Unless Hemogenyx were to be given free money from a charity or a government organisation or a third avenue, then there will always be a detriment to existing shareholders when new money comes onboard and it's not from a raise where everyone had the opportunity to participate.

If it seems unfair, I get it.

But do not forget inviting all shareholders to invest further funds in the company is one of the most expensive, IF not the most expensive way of raising funds.

If you ask me, that is absolutely stupid, it should not be that way, it ought to be the cheapest way, but neither I nor Hemogenyx makes the rules.

IF, Hemogenyx had invited all to participate could we all invest and keep our percentage ownership intact?

And importantly would we all?

I doubt it.

I know I couldn't and from what I read on this board many are not interested in averaging down.

So let's be happy that we are now beyond the discounted raisings and it's comes with warrants at a higher price.

That change is a milestone.

The placee could dump the 250.000 shares next week at a loss and still keep the warrants and I could not care less.

And the reason is the over 400.000 the company have been given to get further good results from HG-CT-1.

Those further positive results are what are going to get a decent amount of money in a JV or VC.

And both of them can be said to be detrimental to existing shareholders as they will also receive a slice of our property.

But let's face it, with no income, that will always be the outcome, there is no other way of raising the cash needed to fully develop our candidates.

So let's bury the jealousy and celebrate the milestone that has been reached (no discounted shares issued)

We have been informed that there is one single buyer for the 250.000 shares.

That equals a 5.75 percent ownership.

(250.000 / 4,343,539 X 100)

Or almost the double of the 3 percent when a shareholder has to declare the holding. Which they have to do within 2 business days after the transaction (which happens on Wednesday 14-5-2025).

If we then give Hemogenyx up to another 2 business days to get the RNS out, I think we can say they have informed the market in a reasonable timeframe.

If we haven't heard about a TR1 by Monday the 19-5-2025, I think it is safe to assume that the buyer has sold either the whole lot or a significant amount to bring them below the 3 percent limit where they by law is required to inform the market.

Unless of course, they want to be breaking the law, breaking the law (gotta get a bit of Judas Priest in there:-)

The BOD have done it again.

Managed to raise funds.

I expect the expenses are lower then 50.000 and that Hemogenyx therefore have more then 400.000 available to secure further positive results regarding HG-CT-1. (More about that later)

Who on earth have given this avenue any thought as a feasible way of securing funds:

"subscribe for the New Ordinary Shares at the Issue Price pursuant to the employee offer exemption under Article 1(4)(i) and 1(5) (h) of the UK Prospectus Regulation"

I am sure, pretty much, no-one.

I am afraid that for that reason, whoever Hemogenyx has been dealing with thought they had us over a barrell and did not put great offer on the table.

If they had, then I doubt this avenue would have been used.

This is a masterstroke by the BOD, to secure further funds in a third way, when we thought our only options were JV or VC.

Well done.

And there is the possibility to get a further 675.000 thought the options over the next 3 years if my head calculations are correct and the invester chose to exercise their options.

I do not know when Patient 2 was injected, but it could be a week ago today, whether it is or not, we are now way beyond the first critical 48 hours with no adverse side affects worthy of an official announcement.

This is very important to me, as this is primarily a dose safety study, so I assume the dose has been increased with patient 2.

We know the previous dose showed efficacy.

I expect a higher dose to be even more effective as long as it has no adverse side effects, and about a week after the second Patient being injected there is no official signs of that.

Great times ahead for patients and shareholders alike.

@Jonnyr

Yeah, there really is no comparison out there.

He is a one of a kind and for that very reason I think it's unfair to expect others to be able to follow suit.

I know, I couldn't

Hi again Saint68.

Thank you for the well wishing and may the goddess of fortune shine on you equally well.

I have been to meetings with Hemogenyx and the amount of people showing up in person I have been able to count on 1 hand, so the desire in this company from it's shareholders does not manifest itself in the same way as it does over in Greatland.

With that in mind, let's be happy that Mr Sandler does not cause unnecessary expense by flying into London to give a 2 hour speech, when it can be done online.

Hi Saint68

Where you at the town hall meeting tonight?

Great to see Shaun Day again as always and as always he delivers.

But I'll argue so does Mr Sandler and Mr Redmond and the BOD.

They are operating in a difficult climate raising funds, are not coming from a position that is automatically considered a position of strength (being cash strong)

Hopefully Mr Sandler will soon be able to paraphrase what Mr. Day said on stage:

"Not bad for a company that couldn't afford potplants in the office not that long ago"

This was in relation to have generated more then 250 million in the first quarter this year and have 398 million Aus fillers in the bank.

To avoid any potential misunderstandings, i do not see that on the horizon for HEMOGENYX for another 10 years, untill CBR is up and running.

For now, I'll be happy to settle for 50 million pounds giving away 20 percent of HG-CT-1.

The BOD of Hemogenyx have gotten us through some tuff times and I believe/hope they will continue to deliver.

If there was ever any doubt, that HEMOGENYX will succeed it should evaporate with the following quote from today's RNS:

"Sir Marc has been at the forefront of promoting effective scientific-medical-pharmaceutical interactions. He has built up a huge network of friends and collaborators who meet regularly in Oxford and who will help Hemogenyx Pharmaceuticals to grow."

Add to this the company's ability to secure funding in the past.

Not necessarily on the term we dream off, but that is the market for you.

I do not see a material change to their ability to continue to be able to secure funding, well other then their headroom having pretty much been used up, but I see it as a positive as it removes some reasons for insecurities about further diluting that has been here on the board in the past.

JV or VC next, unless we get truly non dilutive funding or a loan.

Let's have a discussion about the most likely outcome.

I argue that the most likely source of funding is going to be from a JV with a big pharmaceutical company, simply because that is in their best interest.

But I also think it will be contingent on further success in the clinical trials as it is early days and we only have clinical data from 1 patient so far.

I imagine that funding can be sorted with milestone payments, when targets are being achieved.

I argue that a big pharmaceutical company will prefer to be a partner and only have to deal with one entity, namely HEMOGENYX, rather then have to deal with 2 entities where one of them is a Venture Capitalist fund.

This seems the mist logical approach to me, but then again you can't rely on logic alone as there is no logic explanation why the share price is this low.

There are plenty of people out there willing to take risks, but they are not here (yet:-)

@ Philthehopeful

"Would it not be better to hang fire and get the full result from the first patient before going ahead with a 2nd?"

In my view that would cause an unnecessary delay, there are salaries to be paid every month and although I am sure they still have their hands full with CBR and CDX it HG-CT-1 that is going to be our immediate cash cow.

"With so little money it was a bit of a gamble going ahead with the first but I cant see how they can possibly start a 2nd until they have more money in place "

There was not really an alternative to start the trials, nobody was interested in investing hoping for a good result, they want to know that it works, which is what is being proven up at the moment.

And then hopefully the money and investment will follow.

@JustHereForHemo

Thanks for your last post and sharing your knowledge from conversations with people in the know.

"Vlad raised 700k to give himself the breathing room to negotiate a decent deal with a VC etc"

We might not have been thrilled by the price the money was raised at, but the dilution was "only" in the 10 percent region if I remember correctly.

If the current market conditions does not throw a spanner in the wheel, then I think we might end up being very pleased with what they managed to achieve with the funds they raised.